Jorge A Carrasquillo

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. doi request reprint I-131 Metaiodobenzylguanidine Therapy of Pheochromocytoma and Paraganglioma
    Jorge A Carrasquillo
    Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering, New York, NY Department of Radiology, Weill Cornell Medical Center, New York, NY Electronic address
    Semin Nucl Med 46:203-14. 2016
  2. pmc Imaging and management of a small cell lung cancer metastasis/adrenal adenoma collision tumor: a case report and review of the literature
    Brian R Untch
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    World J Surg Oncol 12:45. 2014
  3. doi request reprint Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancer
    Jorge A Carrasquillo
    Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Eur J Nucl Med Mol Imaging 40:1384-93. 2013
  4. doi request reprint Radionuclide therapy of adrenal tumors
    Jorge A Carrasquillo
    Molecular Imaging and Therapy Service, Radiology Department Memorial Sloan Kettering, USA
    J Surg Oncol 106:632-42. 2012
  5. pmc Molecular imaging of neuroendocrine tumors
    Jorge A Carrasquillo
    Nuclear Medicine Service, Radiology Department Memorial Sloan Kettering, New York, NY, USA
    Semin Oncol 37:662-79. 2010
  6. pmc (124)I-huA33 antibody PET of colorectal cancer
    Jorge A Carrasquillo
    Nuclear Medicine Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Nucl Med 52:1173-80. 2011
  7. doi request reprint Bone-seeking radiopharmaceuticals for treatment of osseous metastases, Part 1: α therapy with 223Ra-dichloride
    Neeta Pandit-Taskar
    Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, New York
    J Nucl Med 55:268-74. 2014
  8. pmc 124I-huA33 antibody uptake is driven by A33 antigen concentration in tissues from colorectal cancer patients imaged by immuno-PET
    Joseph A O'Donoghue
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Nucl Med 52:1878-85. 2011
  9. ncbi request reprint Phase I trial of yttrium 90 resin microspheres in the treatment of colon cancer liver metastases progressing despite hepatic arterial as well as systemic chemotherapy: Preliminary results
    Constantinos T Sofocleous
    Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 30:625. 2012
  10. pmc Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study
    Shakeel Modak
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York
    J Nucl Med 57:231-7. 2016

Collaborators

Detail Information

Publications37

  1. doi request reprint I-131 Metaiodobenzylguanidine Therapy of Pheochromocytoma and Paraganglioma
    Jorge A Carrasquillo
    Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering, New York, NY Department of Radiology, Weill Cornell Medical Center, New York, NY Electronic address
    Semin Nucl Med 46:203-14. 2016
    ..In this report, we review the experience of using I-131 MIBG therapy for targeting pheochromocytoma and paragangliomas. ..
  2. pmc Imaging and management of a small cell lung cancer metastasis/adrenal adenoma collision tumor: a case report and review of the literature
    Brian R Untch
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    World J Surg Oncol 12:45. 2014
    ..We report a case of an adrenal collision tumor composed of a small cell lung carcinoma metastasis and a benign adrenal adenoma identified preoperatively on FDG-PET, CT and MRI and confirmed pathologically...
  3. doi request reprint Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancer
    Jorge A Carrasquillo
    Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Eur J Nucl Med Mol Imaging 40:1384-93. 2013
    ..We conducted a study to better profile the pharmacokinetics, pharmacodynamics, and biodistribution of this agent...
  4. doi request reprint Radionuclide therapy of adrenal tumors
    Jorge A Carrasquillo
    Molecular Imaging and Therapy Service, Radiology Department Memorial Sloan Kettering, USA
    J Surg Oncol 106:632-42. 2012
    ..We will review the experience using radionuclide therapy for targeting PHEO/PGL and NBs...
  5. pmc Molecular imaging of neuroendocrine tumors
    Jorge A Carrasquillo
    Nuclear Medicine Service, Radiology Department Memorial Sloan Kettering, New York, NY, USA
    Semin Oncol 37:662-79. 2010
    ..Here, we review the molecular imaging approaches for NET using various radiopharmaceuticals...
  6. pmc (124)I-huA33 antibody PET of colorectal cancer
    Jorge A Carrasquillo
    Nuclear Medicine Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Nucl Med 52:1173-80. 2011
    ..We also determined the biodistribution of (124)I-huA33 when a large dose of human intravenous IgG (IVIG) was administered to manipulate the Fc receptor or when (124)I-huA33 was given via hepatic arterial infusion (HAI)...
  7. doi request reprint Bone-seeking radiopharmaceuticals for treatment of osseous metastases, Part 1: α therapy with 223Ra-dichloride
    Neeta Pandit-Taskar
    Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, New York
    J Nucl Med 55:268-74. 2014
    ..The review is presented in 2 parts. The first will discuss the characteristics and clinical use of (223)Ra-dichloride, and the second will discuss the β emitters (89)Sr and (153)Sm-EDTMP. ..
  8. pmc 124I-huA33 antibody uptake is driven by A33 antigen concentration in tissues from colorectal cancer patients imaged by immuno-PET
    Joseph A O'Donoghue
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Nucl Med 52:1878-85. 2011
    ..The primary aim of this analysis was to examine the quantitative features of antibody-antigen interactions in tumors and normal tissue after parenteral administration of antitumor antibodies to human patients...
  9. ncbi request reprint Phase I trial of yttrium 90 resin microspheres in the treatment of colon cancer liver metastases progressing despite hepatic arterial as well as systemic chemotherapy: Preliminary results
    Constantinos T Sofocleous
    Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 30:625. 2012
    ....
  10. pmc Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study
    Shakeel Modak
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York
    J Nucl Med 57:231-7. 2016
    ..We hypothesized that arsenic trioxide would enhance the efficacy of the targeted radiotherapeutic agent (131)I-metaiodobenzylguanidine ((131)I-MIBG) and tested the combination in a phase II clinical trial...
  11. ncbi request reprint Copper-64 trastuzumab PET imaging: a reproducibility study
    Jorge A Carrasquillo
    Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, US
    Q J Nucl Med Mol Imaging . 2016
    ..The current study aims to assess the safety, pharmacokinetics, feasibility, and reproducibility of immunoPET imaging with copper-64 (64Cu)-trastuzumab...
  12. ncbi request reprint First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake
    Neeta Pandit-Taskar
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
    J Nucl Med 57:1858-1864. 2016
    ..We conducted a phase I dose-escalation study with 89Zr-desferrioxamine-IAB2M (89Zr-IAB2M), an anti-prostate-specific membrane antigen minibody, in patients with metastatic prostate cancer...
  13. pmc Repetitively dosed docetaxel and ¹⁵³samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer
    Karen A Autio
    Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
    Cancer 119:3186-94. 2013
    ..The toxicity and efficacy when each agent is combined at full, recommended doses, in a repetitive fashion is not well established...
  14. pmc Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity ⁸⁶Y- or ¹⁷⁷Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates
    Sarah M Cheal
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Eur J Nucl Med Mol Imaging 43:925-37. 2016
    ..We tested a pretargeted radioimmunotherapy (PRIT) approach for CRC using a tetravalent bispecific antibody with dual specificity for GPA33 tumor antigen and DOTA-Bn-(radiolanthanide metal) complex...
  15. doi request reprint Surrogate Imaging Biomarkers of Response of Colorectal Liver Metastases After Salvage Radioembolization Using 90Y-Loaded Resin Microspheres
    Waleed Shady
    1 Division of Interventional Radiology, Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Rm H 118, New York, NY 10065
    AJR Am J Roentgenol 207:661-70. 2016
    ..The study also assesses interobserver variability for measuring tumor attenuation using a single 2D ROI on a simple PACS workstation...
  16. pmc A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer
    Neeta Pandit-Taskar
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York Department of Radiology, Weill Cornell Medical College, New York, New York
    Clin Cancer Res 21:5277-85. 2015
    ..We performed a first-in-human phase I/II study of (89)Zr-DFO-huJ591 ((89)Zr-J591) PET/CT immunoscintigraphy to assess performance characteristics for detecting metastases compared with conventional imaging modalities (CIM) and pathology...
  17. pmc PET-based compartmental modeling of (124)I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer
    Pat Zanzonico
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10021, USA
    Eur J Nucl Med Mol Imaging 42:1700-6. 2015
    ..We describe a novel, nonlinear compartmental model using PET-derived data to determine the "best-fit" parameters and model-derived quantities for optimizing biodistribution of intravenously injected (124)I-labeled antitumor antibodies...
  18. pmc Split-dose technique for FDG PET/CT-guided percutaneous ablation: a method to facilitate lesion targeting and to provide immediate assessment of treatment effectiveness
    E Ronan Ryan
    Department of Radiology, Division of Interventional Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Suite H118, New York, NY 10065, USA
    Radiology 268:288-95. 2013
    ..To describe a split-dose technique for fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT)-guided ablation that permits both target localization and evaluation of treatment effectiveness...
  19. pmc ⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer
    Neeta Pandit-Taskar
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Eur J Nucl Med Mol Imaging 41:2093-105. 2014
    ..The purpose of this initial study was to assess safety, biodistribution, normal organ dosimetry, and optimal imaging time post-injection for lesion detection...
  20. pmc Radioembolization as a Salvage Therapy for Heavily Pretreated Patients With Colorectal Cancer Liver Metastases: Factors That Affect Outcomes
    Constantinos T Sofocleous
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY Electronic address
    Clin Colorectal Cancer 14:296-305. 2015
    ..In this study we assessed the efficacy and factors that affect outcomes of radioembolization (RE) using yttrium-90 resin microspheres in patients with unresectable and chemorefractory colorectal cancer liver metastases (CLM)...
  21. doi request reprint Inadvertent intra-arterial injection of (123)I-MIBG in a patient with metastatic pheochromocytoma
    Christian Lohrmann
    From the Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY
    Clin Nucl Med 39:217-8. 2014
    ..During the tracer injection in the left antecubital area, the patient experienced tingling and skin redness in the left forearm and hand. ..
  22. pmc Pilot study of 68Ga-DOTA-F(ab')2-trastuzumab in patients with breast cancer
    Volkan Beylergil
    aDepartment of Radiology, Molecular Imaging and Therapy Service bDepartment of Medicine, Breast Cancer Medicine Service cHuman Oncology and Pathogenesis Program dDepartment of Medical Physics eRadiochemistry and Molecular Imaging Probes Core Facility, Memorial Sloan Kettering Cancer Center Departments of fRadiology gMedicine, Weill Cornell Medical College, New York, New York, USA
    Nucl Med Commun 34:1157-65. 2013
    ....
  23. doi request reprint Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial
    Chaitanya R Divgi
    Columbia University, New York, NY 10032, USA
    J Clin Oncol 31:187-94. 2013
    ..A clinical study to characterize renal masses with positron emission tomography/computed tomography (PET/CT) was undertaken...
  24. doi request reprint Glucose and insulin variations in patients during the time course of a FDG-PET study and implications for the "glucose-corrected" SUV
    Mohiuddin Hadi
    Department of Radiology, University of California, San Francisco, CA 94158, USA
    Nucl Med Biol 35:441-5. 2008
    ..Insulin is also thought to influence tumor uptake by changing uptake in other tissues. However, little attention has been paid to understanding the variability of glucose or insulin during a single PET study...
  25. pmc Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT
    Gary A Ulaner
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York Department of Radiology, Weill Cornell Medical College, New York, New York
    J Nucl Med 57:1523-1528. 2016
    ..Our objective was to determine whether imaging with a human epidermal growth factor receptor 2 (HER2)-targeted PET tracer can detect HER2-positive metastases in patients with HER2-negative primary breast cancer...
  26. pmc Feasibility of Administering High-Dose (131) I-MIBG Therapy to Children with High-Risk Neuroblastoma Without Lead-Lined Rooms
    Bae P Chu
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Pediatr Blood Cancer 63:801-7. 2016
    ..We implemented radiation safety procedures to comply with New York City Department of Health and Mental Hygiene regulations for therapeutic radioisotopes and administered (131) I-MIBG using rolling lead shields...
  27. doi request reprint FDG PET/CT detection of intussusception caused by lymphoma in a pediatric patient
    Hye Jin Kang
    From the Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY Department of Internal Medicine, Division of Hematology Oncology, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Republic of Korea and Pediatric Radiology, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY
    Clin Nucl Med 39:97-8. 2014
    ..The intussusception was successfully managed with medical treatment. We present FDG PET/CT findings in intussusception with non-Hodgkin lymphoma as the lead point in a pediatric patient. ..
  28. doi request reprint Pulsed high-intensity focused ultrasound enhances uptake of radiolabeled monoclonal antibody to human epidermoid tumor in nude mice
    Alfia Khaibullina
    Department of Radiology, Clinical Center, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Nucl Med 49:295-302. 2008
    ..The aim of this study was to determine if pulsed high-intensity focused ultrasound (HIFU) exposures could enhance tumor uptake of (111)In-MX-B3, a murine IgG1kappa monoclonal antibody directed against the Le(y) antigen...
  29. doi request reprint Phase I trial of selective internal radiation therapy for chemorefractory colorectal cancer liver metastases progressing after hepatic arterial pump and systemic chemotherapy
    Constantinos T Sofocleous
    Interventional Radiology, Memorial Sloan Kettering Cancer Center, New York, NY Electronic address
    Clin Colorectal Cancer 13:27-36. 2014
    ....
  30. doi request reprint Radiofrequency ablation of non-small-cell carcinoma of the lung under real-time FDG PET CT guidance
    Helmut Schoellnast
    Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Cardiovasc Intervent Radiol 34:S182-5. 2011
    ..Therefore, before RFA, FDG PET can guide initial needle placement, but it does not serve as a monitoring tool to evaluate residual viable tissue during the procedure...
  31. doi request reprint 18F-FDG uptake in metaphyseal growth arrest lines: a case study
    Remy Lim
    Nuclear Medicine Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Clin Nucl Med 37:993-4. 2012
    ..We describe 18F-FDG uptake in the growth arrest lines of a 7-year-old boy treated for left distal tibial osteosarcoma...
  32. doi request reprint Comparison of 18F-FDG PET/CT and 111In pentetreotide scan for detection of Merkel cell carcinoma
    Yang Lu
    Nuclear Medicine Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Clin Nucl Med 37:759-62. 2012
    ..We reviewed our experience in a limited number of patients who underwent both procedures...
  33. pmc Molecular imaging and therapy of merkel cell carcinoma
    Volkan Beylergil
    Molecular and Imaging Therapy Service, Department of Radiology Box 77, Memorial Sloan Kettering Cancer Center 1275 York Ave, New York, NY 10065, USA
    Cancers (Basel) 6:1020-30. 2014
    ..Continuous progress in the field of molecular imaging might improve management in these patients. The authors review the current modalities and their impact on MCC in this brief review article. ..
  34. pmc Radioimmunotherapy of human tumours
    Steven M Larson
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10065, USA
    Nat Rev Cancer 15:347-60. 2015
    ....
  35. doi request reprint Visualization of orbital involvement of Erdheim-Chester disease on PET/CT
    Volkan Beylergil
    From the Molecular and Imaging Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center Department of Radiology, Weill Cornell Medical Center Developmental Therapeutics Unit, and Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY
    Clin Nucl Med 39:660-1. 2014
    ..An open surgical biopsy of the left orbital mass revealed xanthomatous non-Langerhans histiocytic infiltrate with Touton giant cells, positive for CD68 but negative for CD1a, establishing a diagnosis of Erdheim-Chester disease. ..
  36. doi request reprint FDG PET/CT findings in a rare case of giant fibrovascular polyp of the esophagus harboring atypical lipomatous tumor/well-differentiated liposarcoma
    Volkan Beylergil
    From the Molecular and Imaging Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York Department of Radiology, Weill Cornell Medical Center, New York, NY Department of Radiology, Memorial Sloan Kettering Cancer Center, Basking Ridge, NJ Division of Hematology Oncology, Department of Medicine, and Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY
    Clin Nucl Med 39:288-91. 2014
    ..Mouse double minute 2 homolog amplification was noted by fluorescence in situ hybridization diffusely in the giant polyp consistent with well-differentiated liposarcoma in a giant fibrovascular polyp. ..
  37. pmc Improved tumor imaging and therapy via i.v. IgG-mediated time-sequential modulation of neonatal Fc receptor
    Jaspreet Singh Jaggi
    Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Clin Invest 117:2422-30. 2007
    ..The ability to reduce the serum persistence of conjugated IgG antibodies after their infusion can enhance their therapeutic index, resulting in improved therapeutic and diagnostic efficacy...